164 related articles for article (PubMed ID: 34661454)
1. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
Symcox M; Somaiah N
Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
Symcox M; Jones RL
Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
[TBL] [Abstract][Full Text] [Related]
3. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
4. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
[TBL] [Abstract][Full Text] [Related]
5. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
Wu C; Zhang J; Wu X
Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
[TBL] [Abstract][Full Text] [Related]
6. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.
Fung S; Shirley M
Drugs; 2022 Oct; 82(15):1541-1548. PubMed ID: 36282417
[TBL] [Abstract][Full Text] [Related]
7. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
George S; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Razak AA; Gordon MS; Somaiah N; Jennings J; Meade J; Shi K; Su Y; Ruiz-Soto R; Janku F
Eur J Cancer; 2021 Sep; 155():236-244. PubMed ID: 34391056
[TBL] [Abstract][Full Text] [Related]
8. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
[TBL] [Abstract][Full Text] [Related]
9. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
Schöffski P; George S; Heinrich MC; Zalcberg JR; Bauer S; Gelderblom H; Serrano C; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Becker C; Shi K; Meade J; Ruiz-Soto R; Blay JY; von Mehren M
BMC Cancer; 2022 Dec; 22(1):1302. PubMed ID: 36514034
[TBL] [Abstract][Full Text] [Related]
11. Ripretinib (Qinlock) for GIST.
Med Lett Drugs Ther; 2021 Apr; 63(1621):e56-e57. PubMed ID: 33830971
[No Abstract] [Full Text] [Related]
12. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
Kumar V; Doros L; Thompson M; Mushti SL; Charlab R; Spehalski EI; Zhao H; Thompson MD; Tang S; Pazdur R; Lemery SJ; Theoret MR; Fashoyin-Aje LA
Clin Cancer Res; 2023 Jun; 29(11):2020-2024. PubMed ID: 36485007
[TBL] [Abstract][Full Text] [Related]
14. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
Lemaître J; Watson S
Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
[No Abstract] [Full Text] [Related]
15. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
Li J; Cai S; Zhou Y; Zhang J; Zhou Y; Cao H; Wu X; Deng Y; Huang Z; Dong J; Shen L
Clin Cancer Res; 2022 Aug; 28(16):3425-3432. PubMed ID: 35686969
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study.
Yang W; Qian H; Yang L; Wang P; Qian H; Chu B; Liu Z; Sun J; Wu D; Sun L; Zhou W; Hu J; Chen X; Shou C; Ruan L; Zhang Y; Yu J
Front Oncol; 2023; 13():1180795. PubMed ID: 37274264
[TBL] [Abstract][Full Text] [Related]
17. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
Front Oncol; 2022; 12():883399. PubMed ID: 35847924
[TBL] [Abstract][Full Text] [Related]
18. Ripretinib: First Approval.
Dhillon S
Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors.
Liao W; Xu H; Hutton D; Wu Q; Zhou K; Luo H; Lei W; Feng M; Yang Y; Wen F; Li Q
Front Oncol; 2021; 11():692005. PubMed ID: 34938653
[TBL] [Abstract][Full Text] [Related]
20. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.
Zhang X; Zhang P; Qiu H; Fang Y; Liu H; Zhou Y; Xu H; Yu J; Zhang J; Wang M; Shen L; Li J
Adv Ther; 2023 Sep; 40(9):3817-3829. PubMed ID: 37356078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]